How I approach membrane lung dysfunction in patients receiving ECMO
Critical Care volume 24, Article number: 671 (2020)
With improvements in circuit technology and expanding supportive evidence, extracorporeal membrane oxygenation (ECMO) use has grown rapidly over the past decade . Advances in pump and membrane lung (ML) design have led to simpler and more efficient circuits. Circuit-related complications, however, remain frequent and associated with considerable morbidity .
Mechanisms of membrane lung dysfunction
The ML is responsible for oxygen uptake and carbon dioxide removal. The non-biologic surface of the ML activates inflammatory and coagulation pathways with thrombus formation, fibrinolysis, and leukocyte activation [3,4,5] leading to ML dysfunction. Activation of coagulation and fibrinolysis can precipitate systemic coagulopathy or hemolysis, while clot deposition can obstruct blood flow [6, 7]. Additionally, moisture buildup in the gas phase and protein and cellular debris accumulation in the blood phase may contribute to shunt and dead-space physiology, respectively, impairing gas exchange [8, 9]. These three categories—hematologic abnormalities, mechanical obstruction, and inadequate gas exchange—prompt the majority of ML exchanges.
Membrane lung monitoring
Monitoring of hematologic variables, including coagulation and hemolysis labs, can help identify the development of an ECMO coagulopathy or hemolysis.
The pressure drop across the ML (ΔP) is measured as (Additional file 1: Supplemental Figure):
where PPre = pre-ML pressure, PPost = post-ML pressure.
As clot forms in the ML, increases in resistance (RML) are reflected as increases in ΔP. To correct for changes in blood flow rate (BFR), monitoring of ΔP normalized for BF rate (ΔP/BFR) more directly reflects RML.
Membrane lung gas transfer
Applying the Fick principle across the ML, oxygen (O2) transfer may be calculated as:
where V′O2 = O2 transfer across the ML (mL/min), BFR = blood flow rate (L/min), CxO2 = O2 content of (pre-/post-ML) blood (mL/L) for
where Hb = hemoglobin (g/dL), SxO2 = O2 saturation of (pre-/post-ML) blood, PxO2 = O2 partial pressure of (pre-/post-ML) blood (mmHg).
Measurement of V′O2 provides an objective measure of oxygen transfer and can confirm ML dysfunction, when clinically indicated.
Membrane lung dysfunction
Prompt recognition of ML dysfunction is vital for safety, allowing for elective replacement in a controlled manner. On the other hand, replacement of an adequately functioning device—requiring temporary cessation of ECMO support—places the patient at unnecessary risk while consuming a limited and expensive resource.
Based on the pathophysiology of the ML, replacement may be required for one of three reasons: if there is (A) an associated hematologic abnormality, (B) an increasing obstruction to blood flow, or (C) inadequate gas exchange (Fig. 1).
The presence of an ECMO coagulopathy, typified by elevated clotting times, hypofibrinogenemia, thrombocytopenia, and elevated D-dimer without alternate explanation raises concern for circuit-related coagulopathy (CRC). Alternatively, evidence of hemolysis with elevated plasma-free hemoglobin, without alternate explanation, is concerning for circuit-related hemolysis. In both cases, the diagnosis is presumptive and only confirmed when values normalize after circuit exchange .
Obstruction to blood flow
Increasing ΔP/BFR suggests increasing ML clot burden. As different MLs have different RML, no cut-off values of ΔP define ML dysfunction and the trend should be carefully considered. A rapidly increasing ΔP, even if not associated with reduced gas exchange efficiency, is often a harbinger of impending ML failure and should prompt consideration of ML exchange. When ML pressures are not measured, an increasing pump speed requirement to maintain a stable BFR can serve as a surrogate for increasing ΔP, with the caveat that pump preload and afterload also affect this relationship.
Inadequate oxygen uptake
Worsening oxygenation during ECMO should prompt quantification of oxygen transfer. When the ML is no longer able to meet patient oxygen demand, ML exchange is indicated. There are three important considerations in making this decision.
First, it is necessary that measured V′O2 is truly a maximal value. If circuit BFR is low, for example, the blood will be fully saturated early in the ML path and reserve will exist for additional oxygen transfer as BFR is increased. Similarly, if CPreO2 is artificially elevated, due to high recirculation fraction or impaired tissue extraction, or if the fraction of delivered oxygen in the sweep gas (FDO2) is below 100%, the gradient driving oxygen transfer is reduced, and measured V′O2 may not represent maximal capacity. As such, BFR should be sufficiently high that further increases do not increase arterial saturation, recirculation fraction should be minimized, and ML FDO2 set to 100% to ensure an accurate assessment of maximal V′O2.
Second, though PPost-MLO2 less than 200 mmHg can suggest a failing ML , it is vital to calculate V′O2 for confirmation. In the setting of low CPreO2 or high circuit BFR, blood exiting the ML may not be fully saturated, with low PPostO2, despite normal V′O2. In this case, if the ML is exchanged, the patient is placed at risk without subsequent improvement in oxygen delivery.
Finally, no absolute values diagnose inadequate oxygen transfer and clinical context is important. In general, however, in a patient with hypoxemia and a ML with maximal V′O2 < 100–150 mL/min, ML exchange is typically indicated.
Inadequate carbon dioxide clearance
ML dysfunction can also manifest as inadequate CO2 clearance. Calculation of V′CO2 is not typically performed as it varies in a nonlinear fashion with sweep gas flow rate and requires sampling ML exhaust CO2 . However, persistent PPost-MLCO2 greater than 40 mmHg  and clearance of less than 10 mmHg PCO2 between pre- and post-ML blood gases despite sweep gas flow rates of 10 L/min or greater is suggestive of ML dysfunction and ML exchange should be considered.
Sudden membrane lung failure
While serial monitoring of the ML may identify markers of dysfunction and allow for elective exchange, acute ML failure is a potentially life-threatening event with unique considerations. Mechanisms to ensure optimal management are provided in the Additional file 2.
The decision to exchange a ML is complex and without clear guidelines. In this manuscript, we outline a physiologic approach to troubleshooting this common yet high risk event.
Availability of data and materials
Extracorporeal membrane oxygenation
Coronavirus disease 2019
- ΔP :
Pressure drop across the ML
- P Pre :
- P Post :
- R ML :
Resistance within the ML
Blood flow rate
- V′O2 :
Membrane lung oxygen uptake
- CPreO2 :
O2 content of pre-ML blood
- CPostO2 :
O2 content of post-ML blood
- SPreO2 :
Fractional O2 saturation of pre-ML blood
- SPostO2 :
Fractional O2 saturation of post-ML blood
- PPreO2 :
Partial pressure of pre-ML O2
- PPostO2 :
Partial pressure of post-ML O2
- V′CO2 :
CO2 clearance across the ML
- ExCO2 :
ML exhaust CO2
- FDO2 :
Membrane lung inlet oxygen fraction
- PPreCO2 :
Partial pressure of pre-ML CO2
- PPostCO2 :
Partial pressure of post-ML CO2
International normalized ratio
Activated partial thromboplastin time
Brodie D, Slutsky AS, Combes A. Extracorporeal life support for adults with respiratory failure and related indications: a review. JAMA. 2019;322(6):557–68.
Extracorporeal Life Support Organization. ECLS registry report: international summary. https://www.elso.org/Registry/Statistics/InternationalSummary.aspx. Accessed 4 August 2020.
Dornia C, Philipp A, Bauer S, Lubnow M, Muller T, Lehle K, et al. Analysis of thrombotic deposits in extracorporeal membrane oxygenators by multidetector computed tomography. ASAIO J. 2014;60(6):652–6.
Doyle AJ, Hunt BJ. Current understanding of how extracorporeal membrane oxygenators activate haemostasis and other blood components. Front Med (Lausanne). 2018;5:352.
Maul TM, Massicotte MP, Wearden PD. ECMO biocompatibility: surface coatings, anticoagulation, and coagulation monitoring. In: Firstenberg MS, editor. Extracorporeal Membrane Oxygenation: Advances in Therapy. Croatia: IntechOpen; 2016. p. 30–5.
Lubnow M, Philipp A, Foltan M, Bull Enger T, Lunz D, Bein T, et al. Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange–retrospective analysis of 265 cases. PLoS ONE. 2014;9(12):e112316.
Hastings SM, Deshpande SR, Wagoner S, Maher K, Ku DN. Thrombosis in centrifugal pumps: location and composition in clinical and in vitro circuits. Int J Artif Organs. 2016;39(4):200–4.
Lehle K, Philipp A, Gleich O, Holzamer A, Muller T, Bein T, et al. Efficiency in extracorporeal membrane oxygenation-cellular deposits on polymethylpentene membranes increase resistance to blood flow and reduce gas exchange capacity. ASAIO J. 2008;54(6):612–7.
Epis F, Belliato M. Oxygenator performance and artificial-native lung interaction. J Thorac Dis. 2018;10(Suppl 5):S596–605.
Zakhary B, Sheldrake J, Pellegrino V. Extracorporeal membrane oxygenation and V/Q ratios: an ex vivo analysis of CO2 clearance within the Maquet Quadrox-iD oxygenator. Perfusion. 2020;35(1):29–33.
Ethics approval and consent to participate
Consent for publication
Leen Vercaemst is consultant for Medtronic for conducting/coordinating EMEA region ECMO trainings. Dr. Lorusso is consultant for Medtronic and LivaNova and is on the medical advisory board for Eurosets (all honoraria are paid at the university). Dr. Brodie receives research support from ALung Technologies. He has been on the medical advisory boards for Baxter, Abiomed, Xenios and Hemovent. No other authors report conflicts of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Zakhary, B., Vercaemst, L., Mason, P. et al. How I approach membrane lung dysfunction in patients receiving ECMO. Crit Care 24, 671 (2020). https://doi.org/10.1186/s13054-020-03388-2